Dr. Alex Osimyansky, CEO of Cost Plus Drugs, made the announcement Monday at the White House Roundtable on Health Care Costs.
WASHINGTON — Mark Cubans cost plus pharmaceuticals Co-founder and CEO Dr. Alex Osimyansky said Monday at the White House Roundtable on Health Care Costs that the company will begin manufacturing its drug this week at a testing facility in Dallas’ Deep Ellum neighborhood. Announced.
Osimyansky said the company will begin administering epinephrine, an emergency treatment for allergic reactions, and noradrenaline, a blood pressure medication, to hospitalized patients in intensive care, followed “immediately” by treating pediatric tumors. He said he would administer medicine. No specific date was given.
“Cost Plus Drugs is proudly bringing drug manufacturing back to the United States by leveraging advanced robotics and AI computer vision technology. “We can switch to these types of drugs very quickly, so that whatever product is in short supply, we can start manufacturing that product,” Osimyansky said. “We are very proud to announce that our pilot facility near downtown Dallas has just completed construction, qualification and validation and will begin manufacturing the first commercial batch of product this week. ”
Epinephrine has been in unstable supply since at least 2012, according to Becker’s Hospital Reviews.
“These deficiencies are [pharmacy benefit managers] and wholesalers and a dysfunctional pharmaceutical distribution model. Together, we can put an end to this problem,” Osimyansky said.
Cost Plus Drugs’ 22,000 square foot facility in Deep Ellum was originally scheduled for completion in late 2022.
Now, about two years after it launched, Cost Plus Drugs offers thousands of generic drugs and about 20 name-brand drugs, Beckers said. Website.
Osimyansky also discussed the company’s business model during the roundtable.
“As important as the technology we deploy to bypass PBMs and source programs is the ability to sell products directly when needed without being blocked by intermediaries,” he said. “We are committed to transparency in our pricing, disclosing our actual manufacturing costs and implementing across-the-board price increases. In doing so, we remain profitable and sustainable, but I will never do anything outrageous.”
Mr. Cuban will join state government and the private sector, including Health and Human Services Secretary Xavier Becerra, Federal Trade Commission Chair Lina Khan, and Blue Shield of California Chief Operating Officer Sandra Clark. He attended a roundtable discussion with other stakeholders.
